Phenonet Inc.
- Address
- 23 Juniper Lane
Sponsor Overview
Specializations
Amyotrophic Lateral Sclerosis
Phenonet Inc. is focused on amyotrophic lateral sclerosis, with clinical research centered on the functional needs of people living with mild to moderate disease. Its trial activity is directed toward outcomes relevant to motor neuron degeneration and changes in daily functioning.
- ALS functional assessment
- Motor function preservation
- Neurodegenerative disease care
The sponsor’s research interest in ALS places emphasis on clinically meaningful measures of progression and symptom impact within a neurology setting.
Neuromuscular and Neurodegenerative Disorders
The company’s clinical portfolio reflects a therapeutic interest in neuromuscular disease and broader neurodegenerative disorders, with attention to conditions that affect strength, mobility, and functional independence.
- Neuromuscular impairment
- Progressive weakness
- Functional decline
This area aligns with research aimed at understanding treatment effects on disease-related functional changes in adults with progressive neurological illness.
Supportive and Adjuvant Therapeutic Development
Phenonet Inc. is also active in adjuvant therapy development, with interest in treatment approaches intended to complement existing care in ALS. The sponsor’s work includes evaluation of therapies designed to support overall disease management.
- Adjunctive treatment strategies
- Symptom-directed therapy
- Disease management support
Its research focus includes therapeutic areas where added treatment options may help address the functional burden of progressive neurological disease.
Clinical Outcomes in Functional Neurology
The sponsor’s research landscape includes interest in clinical outcome assessment within functional neurology, using measures that capture changes in mobility, self-care, and overall neurological performance.
- Patient function measurement
- Neurological performance outcomes
- Disease burden assessment
This reflects a therapeutic emphasis on tracking how interventions relate to everyday function in people affected by motor neuron disease.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Evaluation of Sodium Cromoglicate as an Adjuvant Therapy in Mild to Moderate Amyotrophic Lateral Sclerosis: A Phase IIb Randomized, Double-Blind, Placebo-Controlled Study |  Czechia Germany Poland Spain | Recruiting |
Data & Insights
This sponsor works with 1 molecule, of which 0 are not being studied by other sponsors.
This sponsor has worked with 12 sites across their trial portfolio.
Therapeutic Focus
- 1.Nervous System Diseases1 trial449 other sponsors
Partnered Research Centres
12 centres- Address
- Hindenburgdamm 30, Lichterfelde, 12203 Berlin
- Address
- Ul. Popularna 62a, 02-473 Warsaw
- Address
- Marienstr. 72-90, 30171 Hanover
- Address
- Sokolska 581, Novy Hradec Kralove, 500 03 Novy Hradec Kralove
- Address
- Videnska 800, Krc, 140 00 Prague
- Address
- Passeig Maritim De La Barceloneta 25-29, 08003 Barcelona
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Phenonet Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.